A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 May 2014
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 07 Jun 2017 Biomarkers information updated
- 03 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Sep 2010 New trial record